Edible plant exosome-like nanovectors for vaccination
AssigneeUniversity of Louisville Research Foundation, Inc.
InventorHuang-Ge Zhang
Life of this patent
Estimating the term…
Abstract
Provided are compositions and methods for using the same. In some embodiments, the compositions include an EPELN encapsulating and/or having associated therewith an active agent and a plasma membrane derived from a tumor and/or cancer cell coating the EPELN. In some embodiments, the active agent is a therapeutic agent or an immune response modifier, and in some embodiments the plasma membrane has one or more tumor-associated and/or cancer-associated antigens. Also provided are methods for using the compositions for treating tumors and/or cancers, inducing anti-tumor and/or anti-cancer immune responses, activating antigen-presenting cells, targeting CD11c dendritic cells, and preventing or reducing metastasis.
Claims22
A composition comprising:
- an edible-plant derived exosome-like nanoparticle (EPELN) comprising a lipid bilayer encapsulating and/or having associated therewith an immune response modifier;
- wherein the immune response modifier comprises an miRNA selected from the group consisting of miR18a (5′-UAAGGUGCAUCUAGUGCAGAUAG-3′;
- SEQ ID NO:
- 1) and miR17 (5′-CAAAGUGCUUACAGUGCAGGUAG-3′;
- SEQ ID NO:
- 2);
- and
- a plasma membrane;
- wherein the plasma membrane is derived from a tumor and/or cancer cell and wherein the plasma membrane consists of one or more tumor-associated antigens and/or cancer associated antigens.
A method for treating a tumor and/or a cancer, the method comprising administering to a subject in need thereof an effective amount of a composition, the composition comprising:
- (i) an edible-plant derived exosome-like nanoparticle (EPELN) comprising a lipid bilayer encapsulating and/or having associated therewith an immune response modifier;
- wherein the immune modifier comprises an miRNA selected from the group consisting of miR18a (5′-UAAGGUGCAUCUAGUGCAGAUAG-3′;
- SEQ ID NO:
- 1) and miR17 (5′-CAAAGUGCUUACAGUGCAGGUAG-3′;
- SEQ ID NO:
- 2);
- and
- (ii) a plasma membrane derived from a tumor and/or cancer cell coating the EPELN;
- and wherein the plasma membrane consists of one or more tumor-associated antigens and/or cancer associated antigens.
Dependencies are inferred from the claim text.